SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ESH Acquisition Corp. is a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company was founded on November 17, 2021 and is headquartered in New York, NY.

ESH Acquisition Corp - Ordinary Shares - Class A

ESHA is trending due to a massive volume spike and price surge, triggering multiple trading halts, as community discussion focuses on its extremely low float and high insider ownership for a potential short squeeze. Many are comparing it to recent explosive SPACs, with speculative targets suggesting significant upside, fueled by talking points like a rumored "sex toy manufacturer" acquisition. The stock's momentum reflects its position as a key play in the current "SPAC mania" for micro-float tickers.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions (INBS) is rapidly trending due to a potent combination of its extremely low share float and a potential short squeeze, driving significant momentum. The recent announcement of a strategic manufacturing partnership, expected to boost production margins, further amplifies investor interest. The community is actively discussing strong buying defense and a "textbook" short squeeze play as the company continues to expand global adoption of its fingerprint drug screening technology.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in Boston, MA.

Ondas Holdings Inc

Ondas Holdings (ONDS) is trending due to recent autonomous system orders and the FCC's ban on foreign-made drones, which significantly boosts its role in the domestic market. The community is actively discussing a potential short squeeze and anticipating a significant price breakout, with many seeing dips as buying opportunities. This positions Ondas as a crucial player in the growing defense and critical infrastructure sectors for autonomous and counter-drone solutions.

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Corcept Therapeutics Inc

Corcept Therapeutics is trending after the FDA issued a Complete Response Letter for its relacorilant hypertension indication, triggering a sharp stock decline and intense community debate. Investors are divided, with many viewing the sell-off as an overreaction given the company's existing profitable drug and other pipeline programs, while others express caution regarding potential delays and future prospects.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals (VNDA) is trending following its recent FDA approval of NEREUS, the first new motion sickness treatment in over four decades, validating a significant pipeline asset. Community discussion highlights the drug's broader potential for GLP-1 induced nausea, fueling speculation of substantial upside, a potential short squeeze, and even a buyout, given the company's strong financial standing and additional upcoming regulatory catalysts.

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending following its CEO's strategic insights on CNBC and news of spinning off its cloud business into ChronoScale, a move seen by many as unlocking significant value and clarifying its pure-play AI data center infrastructure focus. The community is actively discussing sustained demand from hyperscalers and strong analyst confidence ahead of its upcoming earnings report, fueling bullish sentiment despite recent price volatility. This strategic realignment aims to capitalize on the booming AI infrastructure market with a clearer business model and substantial contracted revenue.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health is trending amidst a wave of strong bearish sentiment, largely attributed to sustained selling pressure, high short interest, and year-end tax loss harvesting. The community is actively discussing the recent FDA approval of Novo Nordisk's oral Wegovy pill, seeing a potential for partnership and a significant catalyst for HIMS's future growth in GLP-1 offerings, alongside its ongoing expansion in D2C lab testing and international markets. Despite current frustration, many long-term investors are using this dip as a buying opportunity, anticipating a strong reversal.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending after rival Corcept Therapeutics received an FDA Complete Response Letter for its Cushing's syndrome drug, effectively removing a near-term competitor for Xeris's Recorlev. The community is buzzing with bullish sentiment, emphasizing Recorlev's blockbuster potential and the significant undervaluation of XERS, further supported by advancing pipeline assets like XP-8121 and robust gross margins.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is trending due to the FDA's acceptance and priority review of its supplemental New Drug Application for AXS-05 in Alzheimer's disease agitation, with an action date anticipated in the near future. This significant regulatory milestone, combined with growing sales of its existing CNS therapies like Auvelity, has ignited immense optimism within the community, with many anticipating substantial long-term value and discussing breakthrough potential.

Motorola Solutions, Inc. engages in the provision of communication infrastructure, devices, accessories, software, and services. It operates through the Products and Systems Integration and Software and Services segments. The Products and Systems Integration segment includes a portfolio of infrastructure, devices, accessories, and video security devices, and the implementation and integration of such systems, devices, and applications. The Software and Services segment focuses on the public safety and enterprise Command Center Software, unified communications applications, and video software solutions. The company was founded on September 25, 1928 and is headquartered in Chicago, IL.

Motorola Solutions Inc

Motorola Solutions ($MSI) is trending following strategic acquisitions in advanced communications and AI-powered video monitoring, reinforcing its leadership in mission-critical technology for public safety and enterprise security. Community sentiment reflects a strong focus on institutional accumulation, evident in large dark pool trades and technical indicators suggesting the stock is oversold, signaling potential for a reversal.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Will 2026 Be a Year for Massive IPOs?

Will 2026 unleash mega IPOs? SpaceX, OpenAI & Anthropic loom large as IPO window reopens. Investors may eye IPO, FPX ETFs for exposure.

Grindr (GRND) is reportedly in talks to go private after a steep decline in its share price placed one of its top shareholders under financial strain, according to people familiar with the matter cited by Semafor.<a href="http://stocktwits.com/symbol/GRND">Grindr’s stock</a> gained as much as&nbsp;11% in midday trade. However, retail sentiment on Stocktwits continued to trend in ‘neutral’ territory amid ‘high’ levels of chatter.The&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.semafor.com/article/10/13/2025/grindr-explores-take-private-after-lender-calls-insiders-loans">report</a> said Raymond Zage and James Lu, who together control a majority of the dating app, are seeking debt financing from Fortress Investment Group to take Grindr private. It added that the discussions gained urgency after a unit of Temasek Holdings, which had issued personal loans to at least one of the two men backed by their Grindr shares, seized and sold some of those holdings last week.The pair has discussed a potential buyout price near $15 a share, though that figure remains in flux, people familiar with the talks said. The report estimated that a deal at that level would value Grindr at about $3 billion.Zage, a U.S. expatriate who now holds Singaporean citizenship,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.investing.com/news/sec-filings/grindr-board-approves-continued-buybacks-as-largest-shareholder-surpasses-50-stake-93CH-4247640">increased</a> his stake in Grindr to more than 50% last month through share buybacks, and Lu, a Chinese-born U.S. citizen, has been a longtime business partner.The move could stabilize Grindr’s stock, which has dropped over nearly 13% since late September despite a 25% year-over-year rise in second-quarter (Q2) profits. Corporate&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001820144/000114036125023187/ny20045745x1_def14a.htm">filings</a> show Zage and Lu pledged a good share of their holdings to personal loans. The report said these were partially seized by SeaTown Holdings, a Temasek unit, last week after becoming undercollateralized.Any transaction could also face scrutiny from U.S. regulators, given Grindr’s past ownership. The app, formerly held by a Chinese firm, was&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.theverge.com/2020/3/6/21168079/grindr-sold-chinese-owner-us-cfius-security-concerns-kunlun-lgbtq">sold</a> in 2020 after The Committee on Foreign Investment in the United States (CFIUS) raised concerns that Beijing could access user data for espionage or blackmail.Even after Monday’s jump in price, Grindr’s stock is still down nearly 26% this year and has barely gained 1% over the past 12 months.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/broadcom-stock-jumps-after-10-billion-ai-infrastructure-deal-with-open-ai/ch6Sji0R3kV">Broadcom Stock Jumps After $10 Billion AI Infrastructure Deal With OpenAI</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a Grindr logo is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Grindr’s Top Shareholders Seek Buyout Deal After Stock Slide: Report 

According to a report by Semafor, the potential buyout is being discussed at around $15 a share.

Equity

Micron Technology and Wendy's have been highlighted as Zacks Bull and Bear of the Day

Micron surges on AI-driven demand and analyst upgrades, while Wendy's sinks under weak sales and bearish revisions.

U.S. IPO Market Rebounding Fast: ETFs Likely to Gain 

IPO activity is rebounding in 2025. Chances of easier Fed policy, a strong stock market, receding trade tensions and AI boom fuel momentum.

Should You Invest in the Red-Hot IPO Market?

The IPO market is heating up; here is a safer to invest.

ETFs to Play IPO Market's Rebound in 2025 

IPO market momentum accelerates as U.S. listings surge, boosting ETFs like FPX, IPO, FPXI and IPOS across the board.

5 American ETFs Witnessing Gains Ahead of Independence Day

SHLD, ARKW, BUZZ and other U.S. ETFs are seeing gains ahead of July 4.


Kenvue Inc. (KVUE) shares&nbsp;will likely draw investor attention Monday morning following a Bloomberg report over the weekend that TOMS Capital had built up an undisclosed stake in the consumer health company and&nbsp;is urging the management to consider a complete sale or separation of some assets.The report, which cited people with knowledge of the matter, comes close to the heels of Kenvue fighting off another activist investor.Earlier this month, the company appointed three new directors, including Starboard Value CEO Jeffrey Smith, to its board as part of an agreement with the activist hedge fund after months of back-and-forth.Starboard, along with its affiliates, owns about 22 million shares, or roughly a 1.1% stake, according to Reuters.Kenvue also named Profitero President Sarah Hofstetter and former head of Bayer's consumer health division Erica Mann as new independent directors.The Bloomberg report did include other details, including the deliberations between the company and TOMS Capital and a timeline for the suggested changes.TOMS has earlier run successful activist campaigns at Kellanova and WillScot Holdings Corp.Kenvue, which owns popular healthcare brands including Band-Aid, Tylenol and Listerine, was spun out of Johnson &amp; Johnson (JNJ) in 2023.Since it began trading independently, Kenvue's stock market value has dropped about 13% to $44.76 billion.On Stocktwits, retail sentiment for the shares&nbsp;ended Friday on an 'extremely bullish'&nbsp;note, largely unchanged from a week back.<figure class="image"><img style="aspect-ratio:774/175;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_24_at_11_35_07_AM_png_2dd82df755.webp" alt="Screenshot 2025-03-24 at 11.35.07 AM.png" width="774" height="175"><figcaption>KVUE sentiment and message volume as of March 21, 2025 | Source: Stocktwits</figcaption></figure>Shares trade at $23.31, up 9.2% year to date. As of press time, Monday's pre-market trading hadn't begun.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Governor of New Jersey Phil Murphy, Kenvue CEO Thibaut Mongon and Mayor of Summit Elizabeth Fagan attend the Kenvue Headquarter Ribbon Cutting Ceremony on March 19, 2025 in Summit, New Jersey. (Photo by Dave Kotinsky/Getty Images for Kenvue)

Kenvue Stock In Focus As TOMS Capital Reportedly Pushes For Sale Or Breakup: Will It Shift Retail Mood?

Earlier this month, the company appointed three new directors, including Starboard Value CEO Jeffrey Smith, to its board as part of an agreement with the activist hedge fund after months of back-and-forth.

Shares of Smithfield Foods Inc. (SFD) were in the spotlight on Friday as the packaged meats-focused company received ‘buy’ ratings from several Wall Street analysts, but retail sentiment stayed cautious.Citi initiated coverage of Smithfield Foods with a ‘Buy’ rating and $27 price target that represented a 28% upside from current levels, The Fly reported.According to the research firm, margin expansion in its packaged meats segment exceeds that seen by its peers. According to the firm, it has further potential to drive profit higher in the coming years, including from share gains in deli and lunchmeats and more stable hog production profit.BofA analyst Peter Galbo also initiated coverage of Smithfield Foods with a ‘Buy’ rating and $28 price target.According to the firm, consumers continue to seek protein rich diets that stand to favor Smithfield's offerings, particularly pork. It noted that Smithfield is the largest vertically integrated U.S. hog producer and fresh pork processor.Goldman Sachs analyst Leah Jordan began coverage with a ‘Buy’ rating and a $32 price target. According to the firm, Smithfield has a "solid growth story" given the company's "industry-leading" packaged meats portfolio.According to Jordan, Smithfield has a compelling total return profile with earnings growth and a 5.5% dividend yield. The firm expects consumers to look for value-added options for convenience and flavor diversity. It also sees an "outsized earnings lift" for Smithfield in the near-term due to a cyclical recovery in hog production with lower feed costs.Retail sentiment on Stocktwits remained ‘neutral’ compared to a week ago. Message volume was in the ‘extremely low’ zone.<figure class="image"><img style="aspect-ratio:1320/312;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2025_02_24_at_12_56_38_PM_44d819b01f.png" alt="Screenshot 2025-02-24 at 12.56.38 PM.png" width="1320" height="312"><figcaption>SFD sentiment meter and message volume on Feb 23</figcaption></figure>Last month, Smithfield priced its initial public offering of 26,086,958 shares at a price of $20 per share.Smithfield Foods focuses on packaged meats and fresh pork products.<a href="https://stocktwits.com/symbol/SFD">Smithfield Foods stock </a>is up 6.9% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Smithfield Foods Earns Multiple 'Buy' Calls On Protein Demand Boom, But Retail Yet To Buy In

 BofA analyst Peter Galbo initiated coverage of Smithfield Foods with a ‘Buy’ rating and $28 price target.

Shares of Reddit, Inc. climbed more than 2% to a fresh record high Monday after the company announced testing of its AI-powered feature, Reddit Answers.The feature, detailed in a blog post, introduces an AI-driven conversational interface allowing users to ask questions and receive curated summaries of Reddit’s community-driven discussions.&nbsp;Reddit Answers highlights relevant snippets, links to related communities, and posts, enabling users to dive deeper into topics.&nbsp;Initially available to a limited number of U.S. users in English, the company plans to expand the feature globally in the future.Reddit stated the rollout aligns with its mission of “empowering communities and providing human perspectives.”&nbsp;The feature aims to enhance search experiences, making them “faster, smarter, and more relevant.”<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_12_09_at_12_30_49_PM_eea45318f3.png" alt="Screenshot 2024-12-09 at 12.30.49 PM.png" width="1314" height="320"><figcaption>RDDT sentiment and message volume on Dec. 9 as of 12:30 pm ET | source: Stocktwits</figcaption></figure>Retail interest in <a href="https://stocktwits.com/symbol/RDDT">Reddit stock</a> soared, with message volume on Stocktwits hitting ‘high’ levels amid ‘neutral’ sentiment.&nbsp;<stembedurl>https://stocktwits.com/PugzNoDrugs/message/595706010</stembedurl><stembedurl>https://stocktwits.com/peloswing/message/595675139</stembedurl>The announcement comes a day after Morgan Stanley upgraded Reddit’s stock to ‘Overweight’ from ‘Equal Weight’, with a price target of $200, up from $70.&nbsp;The brokerage anticipates significant upside from Reddit’s engagement, user growth, and advertising pipelines, projecting ad pricing and ad load improvements.&nbsp;Morgan Stanley also presented a bullish case with a $300 price target, an 85% upside.Since its March IPO, Reddit’s stock has more than tripled.For updates and corrections email newsroom[at]stocktwits[dot]com.

The Reddit logo appears on the screen of a smartphone that rests on top of a laptop keyboard in Reno, United States, on November 28, 2024. (Photo by Jaque Silva/NurPhoto via Getty Images)

Reddit Stock Climbs To Record High On Testing AI-Powered Answers: Retail Chatter Spikes

Initially available to a limited number of U.S. users in English, the company plans to expand the feature globally in the future.

FPX
First Trust Exchange-Traded Fund III - First Trust US Equity Opportunities ETF

Feed

News

Sentiment

Fundamentals

Info

Latest FPX News

FPXFirst Trust Exchange-Traded Fund III - First Trust US Equity Opportunities ETF